CN101959865A - 作为法尼基焦磷酸合酶抑制剂的喹啉类化合物 - Google Patents

作为法尼基焦磷酸合酶抑制剂的喹啉类化合物 Download PDF

Info

Publication number
CN101959865A
CN101959865A CN2009801064544A CN200980106454A CN101959865A CN 101959865 A CN101959865 A CN 101959865A CN 2009801064544 A CN2009801064544 A CN 2009801064544A CN 200980106454 A CN200980106454 A CN 200980106454A CN 101959865 A CN101959865 A CN 101959865A
Authority
CN
China
Prior art keywords
quinoline
amino
naphthalene
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801064544A
Other languages
English (en)
Chinese (zh)
Inventor
R·阿姆斯特费茨
G·博尔德
S·科泰斯塔
W·延克
A·马尔勤兹克
C·穆勒-哈特维格
S·奥夫纳
F·施陶费尔
J·齐默尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101959865A publication Critical patent/CN101959865A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN2009801064544A 2008-02-28 2009-02-26 作为法尼基焦磷酸合酶抑制剂的喹啉类化合物 Pending CN101959865A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08152046 2008-02-28
EP08152046.2 2008-02-28
PCT/EP2009/052314 WO2009106586A1 (en) 2008-02-28 2009-02-26 Quinolines as inhibitors of farnesyl pyrophosphate synthase

Publications (1)

Publication Number Publication Date
CN101959865A true CN101959865A (zh) 2011-01-26

Family

ID=39636965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801064544A Pending CN101959865A (zh) 2008-02-28 2009-02-26 作为法尼基焦磷酸合酶抑制剂的喹啉类化合物

Country Status (11)

Country Link
US (1) US20120094958A1 (enExample)
EP (1) EP2250152A1 (enExample)
JP (1) JP2011514893A (enExample)
KR (1) KR20100124732A (enExample)
CN (1) CN101959865A (enExample)
AU (1) AU2009218468A1 (enExample)
BR (1) BRPI0908396A2 (enExample)
CA (1) CA2717011A1 (enExample)
EA (1) EA201001362A1 (enExample)
MX (1) MX2010009518A (enExample)
WO (1) WO2009106586A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102414180A (zh) * 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
CN104142378A (zh) * 2014-07-29 2014-11-12 华南理工大学 薄层色谱法半定量测定氨基甲酸乙酯的方法
CN112980809A (zh) * 2021-03-17 2021-06-18 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof
CN111440161B (zh) * 2020-05-15 2023-04-14 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254544A (en) * 1992-09-25 1993-10-19 E. R. Squibb & Sons, Inc. Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method
US20020151459A1 (en) * 2000-02-25 2002-10-17 Merck & Co., Inc. Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102414180A (zh) * 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
CN104142378A (zh) * 2014-07-29 2014-11-12 华南理工大学 薄层色谱法半定量测定氨基甲酸乙酯的方法
CN104142378B (zh) * 2014-07-29 2015-12-30 华南理工大学 薄层色谱法半定量测定氨基甲酸乙酯的方法
CN112980809A (zh) * 2021-03-17 2021-06-18 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Also Published As

Publication number Publication date
AU2009218468A1 (en) 2009-09-03
BRPI0908396A2 (pt) 2019-03-06
US20120094958A1 (en) 2012-04-19
KR20100124732A (ko) 2010-11-29
EA201001362A1 (ru) 2011-04-29
JP2011514893A (ja) 2011-05-12
MX2010009518A (es) 2010-09-14
WO2009106586A1 (en) 2009-09-03
EP2250152A1 (en) 2010-11-17
CA2717011A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
CN111647000B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
JP6952695B2 (ja) インフルエンザウイルス複製の阻害剤、その適用方法および使用
JP6171003B2 (ja) ピロロピロリジノン化合物
CN102036955B (zh) 脱乙酰酶b的异羟肟酸盐为基础的抑制剂
US9073898B2 (en) Crystalline form of an inhibitor of MDM2/4 and p53 interaction
CN102015716B (zh) 用于治疗C-Met酪氨酸激酶介导的疾病的咪唑并[1,2-b]哒嗪衍生物
US20120149661A1 (en) Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
CN102827073A (zh) 治疗活性组合物和它们的使用方法
JP7034162B2 (ja) インフルエンザウイルス複製の阻害剤及びその使用
CN103664897A (zh) 二氢嘧啶类化合物及其在药物中的应用
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
EP2948451B1 (en) Substituted purinone compounds
JP2017512783A (ja) ピペリジン−ジオン誘導体
MXPA06005702A (es) Derivados de 1h-imidazoquinolina como inhibidores de quinasa de proteina.
AU2006322187A1 (en) Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
CN101959865A (zh) 作为法尼基焦磷酸合酶抑制剂的喹啉类化合物
JP6002210B2 (ja) １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
US20110288057A1 (en) Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors
CN103459396B (zh) 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
TW202214574A (zh) 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物
TW202146404A (zh) 嘧啶化合物及其醫藥用途
HK40029463A (en) Pyrazine derivative and application thereof in inhibiting shp2
HK40029463B (en) Pyrazine derivative and application thereof in inhibiting shp2
WO2015027914A1 (zh) 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
HK40011744B (en) Inhibitors of influenza virus replication and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110126